KRAS and non-small cell lung carcinoma: Our work identified miR-16 as a key modulator of the primary resistance to TKIs in KRAS-mutated NSCLC and suggests that the restoration of miR-16 in combination with erlotinib or selumetinib may be a promising approach in the treatment of KRAS-mutated NSCLC.